Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venezuelan equine encephalitis virus vaccine
- Development stage
- Preclinical
- Lead developer
- Medigen Biotechnology
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular, Intranasal
01
Overview
The Venezuelan equine encephalitis virus (VEEV) vaccine is designed to protect against Venezuelan equine encephalitis (VEE), a zoonotic infectious disease caused by the mosquito-borne alphavirus VEEV. VEEV can cause febrile illness that may progress to encephalitis in both equines and humans, and is considered a potential bioweapon due to its high infectivity via aerosol. Various vaccine candidates are under development, including live-attenuated, DNA-launched, adenovirus-based, and inactivated virus formulations. Notable investigational candidates include TC-83, a live-attenuated strain used for laboratory and military personnel under an Investigational New Drug (IND) protocol, V3526, a live-attenuated virus derived by site-directed mutagenesis, and V4020, a novel DNA-launched, live-attenuated vaccine with enhanced safety and genetic stability features. Despite ongoing research and several promising candidates, there are currently no VEEV vaccines licensed or approved by the FDA for general human use.
- Other names
- VEEV vaccine
Beyond the preview
Go deeper on venezuelan equine encephalitis virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venezuelan equine encephalitis virus vaccine.